(IN BRIEF) Roche has reported positive outcomes from the RAINBOWFISH study, an investigation into the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA). The study, which included 26 infants aged from birth to six … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland
Tagged Evrysdi, Levi Garraway, Pre-Symptomatic SMA Babies, RAINBOWFISH study, Richard Finkel, Roche, wellness
(IN BRIEF) Roche and Alnylam have entered into a partnership to jointly develop and commercialize zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. Hypertension affects a significant number of adults worldwide and is a major risk factor for … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Pharma & Biotech, Science, Switzerland
Tagged Alnylam, Hypertension Treatment, partnership, RNAi Therapy, Roche, Teresa Graham, Yvonne Greenstreet MBChB, zilebesiran
(IN BRIEF) Roche has announced a collaboration with Eli Lilly to support the development of its Elecsys Amyloid Plasma Panel (EAPP) which is an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease. The EAPP test … Read the full press release
Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, announced that their combination treatment … Read the full press release
Annonce ad hoc conformément à l’art. 53LR (COMMUNIQUÉ DE PRESSE) BÂLE, 19-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionnier mondial des produits pharmaceutiques et des diagnostics axé sur l’avancement de la science pour améliorer la vie des … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged atezolizuma, Avastin®, bevacizumab, cancer du foie, Cancer Immunotherapy, carcinome hépatocellulaire à un stade précoce, CHC, early-stage hepatocellular carcinoma, étude IMbrave050, HCC, IMbrave050 study, immunothérapie anticancéreuse, Levi Garraway M.D. Ph.D., liver cancer, Roche, Tecentriq®
(PRESS RELEASE) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives, has announced that the European Commission has approved Xofluza (baloxavir marboxil), a … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged CHILDREN, infectious disease, influenza, influenza antiviral drug, Levi Garraway, oseltamivir, prevention, Roche, Xofluza treatment
(COMUNICADO DE PRENSA) BASEL, 12-Jan-2023 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY), un pionero mundial en productos farmacéuticos y diagnóstico centrado en el avance de la ciencia para mejorar la vida de las personas, ha anunciado que la … Read the full press release
The company announces FDA clearance for its Alzheimer’s disease Cerebrospinal Fluid (CSF) assays The Elecsys® Alzheimer’s disease (AD) CSF assays will be available on the cobas fully automated immunoassay analyzers, enabling patients to get broad access to high quality testing in a timely … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Alzheimer, beta-amyloid, biomarkers t, CT scan, diagnosis, Elecsys AD CSF Abeta42, Elecsys AD CSF assays, FDA, MRI, pTau181 assays, Roche, tau proteins, Thomas Schinecker
La compañía anuncia la aprobación de la FDA para sus ensayos de líquido cefalorraquídeo (LCR) para la enfermedad de Alzheimer Los ensayos Elecsys® para la enfermedad de Alzheimer (EA) en LCR estarán disponibles en los analizadores de inmunoensayo totalmente automatizados … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Switzerland, Technology
Tagged Alzheimer, beta-amiloide, biomarcadores t, Diagnóstico, Elecsys AD CSF Abeta42, Elecsys Ensayos AD LCR, Elecsys® beta-amiloide, Elecsys® Phospho-Tau, FDA, patología de Alzheimer, proteínas tau, pTau181 ensayos, resonancia magnética, Roche, Thomas Schinecker, tomografía computarizada
The cobas SARS-CoV-2 Qualitative test is one of the first COVID-19 PCR tests performed on an automated, high throughput platform to receive FDA 510(k) clearance. This FDA clearance will ensure that the healthcare community has access to timely, reliable and accurate COVID-19 PCR testing … Read the full press release
Le test qualitatif cobas SARS-CoV-2 est l’un des premiers tests PCR COVID-19 effectués sur une plateforme automatisée à haut débit à recevoir l’autorisation FDA 510(k). Cette autorisation de la FDA garantira que la communauté des soins de santé a accès … Read the full press release
(PRESS RELEASE) LONDON, 6-Jun-2022 — /EuropaWire/ — Haizol launch a new capability to add to their vast array of services, now offering 3D printing to customers worldwide. They have partnered with some of the best manufacturers in China for additive manufacturing to … Read the full press release
Posted in Automotive, Aviation & Aerospace, Business, Electronics & Machinery, Industrial, International Trade, Metals and Minerals, News, Technology, United Kingdom
Tagged 3D printing, 3D printing machines, additive manufacturing, AS9100, casting, china manufacturing, CNC machining, Eastern Bell Capital, fabrication, FDM, Haier, Haizol, Hongtai Capital Holdings, Hybrid Racing, ISO13485, ISO9001, Jennifer Grant, manufacturers in China, metal manufacturing, MicroPort, MJF, molding, OEM, plastic manufacturing, prototyping, Roche, Rocker, Siemens, SLA, SLS, Stala Capital, stamping, Whirlpool, Woofoo Capital, ZEISS
The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people with haemophilia A in locations where there is little to no access to haemophilia treatment Prophylactic treatment aims to prevent bleeds and allow people with haemophilia to achieve quality of life … Read the full press release
Posted in Healthcare, Non Profit, Pharma & Biotech, Switzerland
Tagged acute bleeds, Bill Anderson, bleeding disorders, Cesar Garrido, Chugai, Dr Osamu Okuda, Haemophilia A, Humanitarian Aid Program, prophylactic treatment, prophylaxis, Roche, WFH Humanitarian Aid Program, World Federation of Hemophilia
El compromiso renovado proporcionará tratamiento preventivo (profiláctico) continuo a hasta 1000 personas con hemofilia A en lugares donde hay poco o ningún acceso al tratamiento de la hemofilia. El tratamiento profiláctico tiene como objetivo prevenir las hemorragias y permitir que las personas … Read the full press release
Posted in News
Tagged acute bleeds, Bill Anderson, bleeding disorders, Cesar Garrido, Chugai, Dr Osamu Okuda, Dr. Osamu Okuda, Federación Mundial de Hemofilia, Haemophilia A, hemofilia A, hemorragias agudas, Humanitarian Aid Program, profilaxis, Programa de ayuda humanitaria, Programa de ayuda humanitaria de la FMH, prophylactic treatment, prophylaxis, Roche, trastornos hemorrágicos, tratamiento profiláctico, WFH Humanitarian Aid Program, World Federation of Hemophilia
(PRESS RELEASE) PARIS, 28-Apr-2022 — /EuropaWire/ — ATTD 2022 – Diabeloop, pioneer in therapeutic artificial intelligence for diabetes management, presents today new results from a real-life cohort in Germany. The data show a constant improvement in Time In Range (70-180 … Read the full press release
Posted in Artificial Intelligence (AI), Denmark, France, Healthcare, News, Pharma & Biotech, Science, Spain, Technology
Tagged Accu-Chek Insight, AI, aid, artificial-intelligence, ATTD 2022, automated insulin delivery, biphasic boluses, blood sugar level, DBL-hu, DBLG1, DBLG1 iController, DBLG1 System, Diabeloop, Diabetes, diabetes management, Erik Huneker, glucose control, glycemic control, HbA1c, Insulin Pump, postprandial hyperglycemia, Prof. Pierre-Yves Benhamou, real-life DBLG1 cohort, reduction of hypoglycemia, reduction of hypoglycemic episodes, Roche, Stéphanie JEGU, T1D, Time In Range, TIR, type 1 diabetes, WP7, WP72 study, YourLoops
Dans les études YOSEMITE et RHINE sur l’œdème maculaire diabétique, au moins 60 % des patients Vabysmo éligibles pourraient prolonger le traitement à tous les quatre mois à deux ans, contre 50 % à la première année Près de 80 % des … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged affections rétiniennes, angiogenèse, anticorps bispécifique, DME, DMLA néovasculaire, exsudation et dégénérescence 2022, injections oculaires, Levi Garraway MD Ph.D., médecine oculaire, perte de vision, ranibizumab, RHIN, Roche, Susvimo, Susvimo Archway, Vabysmo, YOSEMITE, œdème maculaire diabétique
In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one Almost 80% of eligible Vabysmo patients could extend treatment to every … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland
Tagged Angiogenesis, bispecific antibody, diabetic macular edema, DME, Exudation and Degeneration 2022, eye injections, eye medicine, Levi Garraway M.D. Ph.D., Neovascular AMD, ranibizumab, retinal conditions, RHINE, Roche, Susvimo, Susvimo Archway, Vabysmo, vision loss, YOSEMITE
People with moderate or mild haemophilia A have significant unmet clinical needs, as this population may not use preventative treatments due to missed or delayed diagnoses of bleeding episodes and a lack of treatment guidelines1,2 New data indicate that Hemlibra has a favourable safety profile in … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged American Society of Hematology, ASH, bleeding, blood clotting, blood disease, Chugai, Chugai Pharmaceutical, diagnostics, emicizumab, Genentech, haemophilia, Haemophilia A, HAVEN 6, Hemlibra®, Levi Garraway, pharmaceuticals, pharmacodynamics, pharmacokinetics, phase III HAVEN 6 study, prophylactic, Roche
Next-generation sequencing (NGS) enables a better understanding of genetic mechanisms linked to specific diseases and is helping drive personalised healthcare Preparing DNA for sequencing libraries is complex and prone to human error, which can interfere with accurate sequencing results The new AVENIO … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged advance sequencing technologies, AVENIO Edge System, diagnostic solutions, diagnostics, In Vitro Diagnostics, integrated sequencing, IVD, next-generation sequencing, NGS, Roche, sequencing library preparation, Thomas Schinecker
Every year, over 604,000 women worldwide are diagnosed with cervical cancer and approximately 342,000 die from this preventable disease, caused by Infection with high-risk human papillomavirus (HPV). As recently published in the International Journal of Cancer, the IMPACT (IMproving Primary screening And Colposcopy … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Switzerland, Technology
Tagged biomarker, cervical cancer, cervical cells, cervical pre-cancers, CINtec PLUS Cytology, Colposcopy Triage, HPV, HPV-positive women, human papillomavirus, impact, International Journal of Cancer, Pap cytology, Roche, testing
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?